Arbutus Biopharma
ABUS

$3.90

0.51%

Market Cap: 736M

About: Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Employees: 73

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

688% more call options, than puts

Call options by funds: $12.8M | Put options by funds: $1.63M

62% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 13

9% more capital invested

Capital invested by funds: $196M [Q4 2023] → $214M (+$17.7M) [Q1 2024]

8% more funds holding

Funds holding: 106 [Q4 2023] → 114 (+8) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 4 (+0) [Q1 2024]

0.6% less ownership

Funds ownership: 46.86% [Q4 2023] → 46.25% (-0.6%) [Q1 2024]

9% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 34

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$4

3%

upside

Avg. target

$4.43

14%

upside

High target

$5

28%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Ed Arce	28%upside $5	Buy Reiterated	7 Jun 2024
HC Wainwright & Co. Ed Arce	28%upside $5	Buy Reiterated	6 Jun 2024
Chardan Capital Keay Nakae	3%upside $4	Buy Maintained	5 Jun 2024
Chardan Capital Keay Nakae	3%upside $4	Buy Reiterated	3 May 2024
JMP Securities Roy Buchanan	3%upside $4	Market Outperform Reiterated	4 Apr 2024

See Analyst Rankings

Financial journalist opinion

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its second quarter 2024 financial results and corporate update for Thursday, August 1, 2024. The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially leading to a functional cure for chronic hepatitis B. ABUS is engaged in significant IP litigation with Moderna, Pfizer, and BioNTech over LNP technology used in mRNA vaccines.

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus Distributors Ltd. News Release

VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Mr. Peter Bull and Arbutus Distributors Ltd. (“Arbutus”), a private investment and holding company controlled by Mr. Bull, announced today that Mr. Bull and Arbutus disposed of an aggregate of 2,050,000 common shares (the “Subject Shares”) of ADENTRA Inc. (“ADENTRA”) at a sale price of $38.06 per Subject Share for aggregate gross proceeds of $78,023,000 on the Toronto Stock Exchange through a block sale on May 31, 2024 (the “Transaction”). ADENTRA is incorporated under the federal laws of Canada and has its head office at #B340 20161 86th Avenue, Langley, British Columbia, V2Y 2C1.

Arbutus Distributors Ltd. News Release

Arbutus to Participate in Jefferies Global Healthcare Conference

WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York:

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy.

Arbutus to Present Imdusiran Data at EASL Congress 2024

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

NEW YORK--(BUSINESS WIRE)--Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the second largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) (“Arbutus” or the “Company”) with an ownership interest of approximately 6.8% of the Company's outstanding shares, today published an open letter to shareholders outlining its views of the best paths forward to maximize value. The full text of the letter is below:.

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q1 2024 Earnings Conference Call May 2, 2024 8:45 AM ET Company Participants Lisa Caperelli - Vice President, Investor Relations Mike McElhaugh - Interim President and Chief Executive Officer and Director Mike Sofia - Chief Medical Officer Karen Sims - Chief Medical Officer David Hastings - Chief Financial Officer Conference Call Participants Dennis Ding - Jefferies Thomas Yip - H.C. Wainwright Roy Buchanan - Citizens JMP Keay Nakae - Chardan Operator Good day, and thank you for standing by.

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

See News Rankings